This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCormack, J. P.
Right arrow Articles by Rangno, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCormack, J. P.
Right arrow Articles by Rangno, R.
Related Collections
Right arrow Adverse drug reactions
CMAJ • June 25, 2002; 166 (13)
© 2002 Canadian Medical Association or its licensors

Letters
Correspondance

Digging for data from the COX-2 trials

James P. McCormack* and Robert Rangno{dagger}

Associate Professor, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BCRobert Rangno Associate Professor, Departments of Medicine and Pharmacology, University of British Columbia, Vancouver, BC

We agree with Joel Lexchin's request for more access to the information from randomized controlled trials on new drugs.1 To that end we felt CMAJ readers would find a brief synopsis of some of the findings from the latest cyclooxygenase-2 (COX-2) inhibitor trials valuable so that they could make informed decisions about the safety issues associated with these new agents compared with older NSAIDs.

Randomized controlled trials are the best way of determining whether a cause–effect relation exists between treatment and outcome.2 They are also one of the best ways to determine if there are important clinical differences in efficacy or safety between therapies. In the last year or so, 2 trials looking at the safety of the COX-2 inhibitors have been published.3,4 These results have been used to suggest that the COX-2 inhibitors are safer than older NSAIDs. However, the US Food and Drug Administration (FDA) has not put these agents in a class by themselves.5 Recently, Mucklow has suggested that journal reporting of clinical trial adverse events is inadequate.6 Since February 2001 it has been possible to review more complete trial results on the FDA Web site. Unfortunately, the data on this Web site are presented in numerous reports and it is difficult and time-consuming to get a complete picture of the overall differences in clinical end points. A synopsis of the information at this Web site follows. We chose to present primarily those end points that we felt readers would find interesesting, as well as results that were statistically different. Biochemical and laboratory test differences are not reported in this synopsis. The percentages presented are the crude incidence rates. Numerous subset analyses of the information are also presented at the FDA Web site, but a discussion of these data is beyond the scope of this letter. More detailed trial reports are available at www .fda .gov /ohrms /dockets/ac/01 /briefing/3677b1_03_med.doc and www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_03_med.doc.

Results of the CLASS trial as reported in JAMA are presented in Table 1.3 The CLASS trial was actually a planned pooled analysis of 2 trials, one comparing ibuprofen with celecoxib and the other comparing diclofenac with celecoxib. In the JAMA article the CLASS trial was presented as a 6-month trial (mean duration of exposure 4 months).3 However, the trial comparing ibuprofen with celecoxib was 15 months long (mean duration of exposure 7 months) and the trial comparing diclofenac and celecoxib trial was 12 months long (mean duration of exposure 6.5 months). A synopsis of the overall results of these 2 trials and a more complete presentation of the adverse events that occurred are presented in Table 2.


View this table:
[in this window]
[in a new window]
  		Table 1.

 

View this table:
[in this window]
[in a new window]
  		Table 2.

 

Results of the VIGOR trial are presented in Table 3. Results from the FDA Web site are virtually the same as those presented in the published version of this 9-month trial.4 The data presented in boldface are from the FDA Web site and were not presented in the N Engl J Med article.4


View this table:
[in this window]
[in a new window]
  		Table 3.

 

The interpretation of the clinical importance of these results compared with the published data in journals is left to the reader.

James P. McCormack Associate Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC Robert Rangno Associate Professor Departments of Medicine and Pharmacology University of British Columbia

Vancouver, BC

References

  1. Lexchin J. Inaccessibility of drug reports [letter]. CMAJ 2002;166(10):1251.[Free Full Text]
  2. Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? BMJ 1998;316:201.[Free Full Text]
  3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.[Abstract/Free Full Text]
  4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-8.[Abstract/Free Full Text]
  5. Gottlieb S. FDA refuses companies' request to drop ulcer warning. BMJ 2001;322:385.[Free Full Text]
  6. Mucklow JC. Reporting drug safety in clinical trials: getting the emphasis right. Lancet 2001; 357: 1384.[Medline]



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
A. Gaffo, K. G. Saag, and J. R. Curtis
Treatment of rheumatoid arthritis
Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Chaiamnuay, J. J. Allison, and J. R. Curtis
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. L. Gluud
Bias in Clinical Intervention Research
Am. J. Epidemiol., March 15, 2006; 163(6): 493 - 501.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. M. Wright
The double-edged sword of COX-2 selective NSAIDs
Can. Med. Assoc. J., November 12, 2002; 167(10): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
E. Wooltorton
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex)
Can. Med. Assoc. J., June 1, 2002; 166(13): 1692 - 1693.
[Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCormack, J. P.
Right arrow Articles by Rangno, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCormack, J. P.
Right arrow Articles by Rangno, R.
Related Collections
Right arrow Adverse drug reactions